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 Abstract - This study presents the results of pre-
participation musculoskeletal and cardiac screening 
using the Lausanne recommendations, which include 
a personal and family history, physical examination 
and electrocardiography. Cross sectional study using 
the Lausanne screenings and the European Society of 
Cardiology (ESC) recommendations carried out at 
Al-Ahli club in Dubai, United Arab Emirates. 230 
male athletes participating in organised sports were 
included. Exclusion criteria were those under 14 or 
over 35 years old, females and athletes with 
established cardiovascular disease. Primary outcome 
are the results of Lausanne screening with outline of 
the negative, positive and false positive results and 
number needed to screen. Secondary outcomes 
include the results of musculoskeletal and 
neurological screening. A total of 174 (76%) athletes 
had a negative screening result. Fifty-four athletes 
(23%) underwent additional testing. Forty-seven 
athletes (20.4%) had false positive screening results. 
Seven athletes (3%) had a positive screening result 
and four athletes (2%) were restricted from sport. 
The number of athletes needed to screen to detect 
one lethal cardiovascular condition was 33 athletes. 
The Lausanne recommendations are well suited for 
the United Arab Emirates. The number needed to 
screen to detect one athlete with serious 
cardiovascular disease is acceptable at 33. 
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I.  INTRODUCTION 
 
 Sudden cardiac death (SCD) is the 
leading cause of mortality in young athletes during 
exercise, and may result from undiagnosed structural or 
electrical cardiovascular disease(1, 2). The incidence of 
SCD in young athletes varies widely from 0.5-
2/100,000/year(3, 4). Sporting activity doubles the relative 
risk of SCD(5). Pre-participation evaluation in athletes has 
been implemented in Europe and USA over last decades. 
In 2005, the European Society of Cardiology (ESC) 
proposed a common European protocol of cardiovascular 
pre-participation screening in athletes to prevent risk and 
occurrence of sudden cardiac death(6). Firstly proposed in 
Italy(4), this screening consists of taking family and 
personal history, and undertaking physical examination, 
and electrocardiographic assessment. Interestingly, the 
incidence of sudden cardiovascular death in young 
competitive athletes has been significantly reduced(7). 
The success of this screening protocol can well be related 
to the inclusion of electrocardiography in the screening 
protocol. Specifically, electrocardiography, which is very 
sensitive to diagnose hypertrophic cardiomyopathy, 
allows to identify those athletes at risk of sudden cardiac 
death, suffering from underlying cardiac abnormalities(8-
11). Based on the Lausanne recommendations, the 
International Olympic Committee has approved the 
European Society of Cardiology recommendations or pre-
participation cardiovascular screening in athletes (12). 
The current recommendations of the American 
Heart Association (PPE-4) for athletes include a detailed 
history and physical examination. In athletes, 75% of 
medical and orthopedic conditions can be assessed 
administering a detailed questionnaire(13), but the 
evidence highlights that the American pre-participation 
approach is not effective to prevent or detect the risk of 
sudden cardiac death(14).  
Screening of the conditions predisposing to 
sudden cardiac death is still debated. Specifically, the cost 
benefit of using electrocardiography is debatable, 
especially if the screening is used to prevent the sudden 
death associated with rare hereditary disease(15). 
Since musculoskeletal and neurological injuries are 
frequent in athletes, with specific patterns for different 
sports (16), it is important that athletes undergo periodic 
pre-participation assessment as guarantee of safety. 
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Following the Lausanne recommendations, we undertook 
pre-participation evaluation as screening protocol for 
United Arab Emirates athletes. The aim of this study is to 
ascertain the effectiveness of this protocol to detect hidden 
cardiac disorders, and prevent the occurrence of sudden 
cardiac death. 
 
II.  METHODOLOGY 
 
 The Dubai Health Authority approved 
all procedures described in the present investigation, and 
subjects gave their consent to participate in the study. 
Both parents signed the consent if the subjects were 
younger than 16 years of age. 
Participants: Two hundred thirty males competitive 
athletes, from a sport club in the United Arab Emirates, 
were examined from December 2011 to February 2012. 
Exclusion criteria were age under 14 and over 35, female 
gender, and diagnosis or history of cardiovascular disease. 
Once a station-based evaluation offered a time-efficient 
and cost-effective examination, all participants were 
assessed on a day off training. Recruitment was through 
general announcement at the club. 
Medical questionnaire: A standard questionnaire was 
administered to all participants. It was set up according 
the Lausanne recommendations; the Arabic translation 
was approved by the Dubai Health Authority. If athletes 
did acknowledge of family history of sudden death or 
cardiac disease, parents and siblings were also 
investigated.  
Physical examination: A single fellowship trained sport 
physician performed all examinations according to the 4th 
Edition of the American Preparticipation Physical 
Examination (PPE-4) criteria. Cardiac examination was 
based on the ESC Sport's Cardiology Section Consensus 
statement(6). Measurement of height (cm) and body mass 
(kg), brachial artery blood pressure in the seated position 
(mm Hg), precordial auscultation in both supine and 
standing positions, and examination of Marfan syndrome 
characteristics was undertaken by a cardiologist 
experienced in athlete’s heart syndrome. 
Resting 12-lead electrocardiography: 
Electrocardiography was conducted using regularly 
calibrated and maintained machines (Philips PageWriter 
TC50; Philips Healthcare, The Netherlands). The 
electrodes were placed to ensure consistency of the 
precordial lead locations. The electrocardiograph traces 
were printed as hard copy for later analysis, and assessed 
independently by the cardiologist. PR interval, QRS 
duration, QT interval, QRS axis, Q, R, S and T wave 
voltage, and ST segments were measured at each lead.   P 
wave voltage was measured at the V1 lead alone. Left axis 
deviation was defined as a QRS axis more negative than -
30°, and right axis deviation as a QRS axis more positive 
than +120°. The QT intervals were corrected for heart rate 
(QTc) using Bazett’s formula. A QTc interval was 
considered abnormally prolonged if >450 ms in males. 
Right atrial enlargement was defined as a P wave voltage 
≥0.25 mV. Left atrial enlargement was defined as a 
biphasic P wave in V1 where the terminal portion was 
more negative than -0.1 mV and ≥0.04 seconds long. Left 
and right ventricular hypertrophy was determined by the 
Sokolow–Lyon voltage criteria. Left ventricular 
hypertrophy (LVH) was defined by the sum of the S wave 
in V1 and the R wave in either V5 or V6 being >3.5 mV. 
Right ventricular hypertrophy was defined by the sum of 
the R in V1 and the S in V6 being >1.05 mV. In addition, 
the presence of LVH was assessed by the Romhilt and 
Estes point-score system with a score of ≥5 being used to 
define LVH. A Q wave was considered abnormal or 
pathological if >0.04 seconds long and/or if the depth of 
the Q wave was >5% of the height of the R wave. 
Stages of testing: The Lausanne recommendations were 
followed. In step 1, all athletes had a 12-lead electrocardi-
ogram. A positive personal history, a family history that 
indicated the possibility of inherited cardiac disease, posi-
tive physical examination or electrocardiographic findings 
from step 1 prompted further evaluation by an expert car-
diologist at a tertiary referral hospital, which included any 
one or a combination of echocardiography, 24-hour Holter 
electrocardiography, stress test, electrophysiology test, 
and even MRI. Symptoms considered to be suggestive of 
a possible underlying cardiovascular disorder included 
repetitive syncope during exercise, prolonged periods of 
palpitations, sustained chest pain and unexplained sudden 
death in a first degree relative aged <35 years. Athletes 
with soft murmurs (grade I) not radiated, or who had no 
electrocardiographic changes, were deemed to have flow 
murmurs requiring no further action. A flow diagram 
illustrates the screening protocol for (Figure 1). 
Statistical analysis: The statistical analysis was 
conducted using computer program SPSS version 20. The 
qualitative questionnaire results were expressed in 
absolute numbers form and centile values. Descriptive 
statistics included mean and standard deviation. All results 
are presented descriptively.  
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Tab. 1. Population characteristics. 
 
of sprain, and 36 athletes (15.7%) had a history 
of muscle strain. 
Physical examination 
Table 3 shows the distribution of athletes with 
positive finding on physical examination. Ten athletes 
(4.3%) had scoliosis, four athletes (1.7%) chronic 
shoulder instability, ten athletes (4.3%) chronic ankle 
instability, and 60 athletes (26.1%) pes planus. Three 
athletes (3.1%) had undergone anterior cruciate ligament 
reconstruction, and three athletes (3.1%) had undergone 
meniscectomy. One athlete had a palpable spleen. 
Cardiac history and examination 
Two athletes had a positive family history of 
sudden cardiac death before the age of 35 years.  Six 
athletes (2.6%) had a positive history of fainting, nine 
athletes (3.9%) complained of dizziness, two athletes 
(2.2%) had shortness of breath, three athletes (1.3%) 
complained of chest pain, and three athletes (1.3%) 
complained of palpitation during or after exertion (table 
2). Following our examination, two athletes (0.9%) were 
diagnosed with hypertension, and seven (3%) had a 
benign systolic ejection murmur (table 3). 
Electrocardiography 
Table 4 shows all ECG findings. Forty-eight 
athletes had an abnormal ECG according to the 2010 
European Society of Cardiology recommendations. The 
most common abnormalities were abnormal T wave 
inversion (10.4%). Two athletes had patterns of Wolff-
Parkinson-White syndrome, one athlete prolonged QT, 
and one athlete atrial fibrillation. 
Additional Tests (stage 2)  
Table 5 shows the results of stage 2 testing. All 
positive cases form stage 1 underwent further testing with 
no loss to follow up. Two athletes had a systolic brachial 
blood pressure above 140 mm Hg on more than one 
reading and were referred to their family physician for 
treatment. A total of 54 (23.5%) had abnormalities at the 
stage 1 of screening, the reason for the additional tests 
(stage 2). Diagnosis was confirmed in seven athletes (3%). 
Figure 2 shows the overview of screening stages, and 
table 6 gives an overview of the athletes diagnosed with 
cardiovascular conditions.   
Cardiac history subjects 
Six athletes had a positive cardiac history, all with normal 
ECG; they underwent echocardiography, and only one 
athlete was confirmed to have minor insufficient mitral 
valve.  
 
Abnormal electrocardiography subjects 
Forty eight athletes had ECG abnormalities 
necessitating further investigations. Two athletes (0.8%) 
were diagnosed with Wolff-Parkinson-White syndrome 
following stress ECG, 24-hour Holter and 
electrophysiology studies showing accessory pathway. 
Both athletes had no symptoms, opted for ablation and 
returned to play. One athlete (0.4%) had atrial fibrillation 
on ECG with history of shortness of breath on exertion. 
His ECG showed an enlarged left atrium, both exercise 
test and 24-hour Holter confirmed the diagnosis of atrial 
fibrillation, and he underwent ablation with temporary 
restriction from sport. One athlete (0.4%) had positive 
history of palpitation and positive ECG for T-wave 
inversions across all leads; his echocardiography showed 
right ventricular dilatation and hypokinesia; stress test, 24-
hour Holter and MRI confirmed the diagnosis of 
arrhythmogenic right ventricular cardiomyopathy. One 
athlete (0.4%) was diagnosed with myocardial ischemia 
following a positive history of chest pain and positive 
ECG of ST depression. He had further tests, including 
echocardiography, which showed minor tricuspid and 
mitral regurgitation, and stress ECG and MRI testing 
confirmed the diagnosis. Finally, one athlete (0.4%) was 
diagnosed with prolonged QT syndrome; he had positive 
history of syncope with exertion, positive family history 
of sudden cardiac death with ECG of borderline QT 






                                                                                 Total (n = 230) 
Mean age (SD), y 20.68 (±5.22) 
Mean height (SD), cm 169.13(±10.82) 
Mean weight (SD), kg 62.68(±14.61) 
Mean body mass index (SD),  kg/m2 21.80(±4.17) 
Mean body surface area (SD), m2 1.71(±0.24) 
Mean pulse rate (SD), BPM 61.54(±12.70) 
Mean systolic BP (SD), mm Hg 123.47(±13.47) 
Mean diastolic BP (SD), mmHg 68.28(±7.80) 
Mean total training time (SD) hours/week 10.06(±0.99) 
Teams n (%) 
Football-First team 36(15.7) 
Football-Reserve 20(8.7) 






Handball-First team 33(14.3) 
Basketball-First team 27(11.7) 
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Total (n = 230) 
Question                                                                                 Yes, n
(%) 
No, n (%) 
GENERAL MEDICAL 
Have you ever had a preparticipation 
evaluation? 
34(14.8) 196(85.2) 
Did you suffer an injury last season? 53(23) 177(77) 
Do you have a chronic injury? 26(11.3) 204(88.7) 
Have you ever been hospitalized? 50(21.7) 180(78.3) 
Are you taking any medications at the 
present time? 
25(10.9) 205(89.1) 
Are you taking any nutritional 
supplements? 
32(13.9) 198(86.1) 
Do you have any allergies? 21(9.1) 209(90.9) 
Do you have a family history of diabetes 
mellitus? 
117(50.9) 113(49.1) 
Do you suffer from any skin condition? 39(17) 191(83.0) 
Have you ever been treated for asthma? 13(5.7) 217(94.3) 
Have you ever had a heat injury? 20(8.7) 210(91.3) 
Do you suffer from vision problem? 41(17.8) 189(82.2) 
Do you use eye glasses or contact lenses? 19(8.3) 211(91.7) 
Are you trying to reduce or increase your 
weight? 
115(50) 115(50) 
Do you feel nervous/ anxious before a 
game? 
21(9.1) 209(90.6) 
Do you smoke? 17(7.4) 213(92.6) 
CARDIOVASCULAR SYSTEM 
Have you ever fainted or passed out during 
/ after exertion? 
6(2.6) 224(97.4) 
Have you ever been dizzy during / after 
exertion? 
9(3.9) 221(96.1) 
Have you ever had chest pain or tightness 
during / after exertion? 
3(1.3) 227(98.7) 
Do you get tired more quickly than your 
friends during exercise? 
5(2.2) 225(97.8) 
Have you ever had shortness of breath that 
made it difficult to perform sport? 
2(0.9) 228(99.1) 
Have you ever had racing heart or skipped 
heartbeats? 
3(1.3) 227(98.7) 
Have you ever been told you have a high 
blood pressure? 
0(0.0) 230(100) 
Have you ever been told you have high 
cholesterol? 
0(0.0) 230(100) 
Have you even been told you have a heart 
condition? 
2(0.9) 228(99.1) 
Has anyone in your family with less than 35 




Have you ever had head injury? 36(15.7) 194(84.3) 
Did you suffer from loss of consciousness or 
temporary loss of memory? 
7(3) 223(97) 
Do you complain of continuous headache? 19(8.3) 211(91.7) 
Have you ever had a seizure? 0(0.0) 230(100) 
Have you ever complained of limb 
numbness or tingling? 
16(7) 214(93) 
MUSCULOSKELETAL SYSTEM 
Do you use any protective gear during your 
game? 
54(23.5) 176(76.5) 
Do you use any taping or bracing during 
your game? 
40(17.4) 190(82.6) 
Have you ever had a fracture or 
dislocation? 
67(29.1) 163(70.9) 
Have you ever had a joint sprain? 65(28.3) 165(71.7) 
Have you ever had a muscle strain? 36(15.7) 194(84.3) 
 





IV.  DISCUSSION 
 
 The Lausanne recommendations have been 
widely debated since their endorsement by the 
International Olympic Committee in 2006(12). According 
to Corrado and colleagues(6), we included resting 
electrocardiography to detect cardiac abnormalities such 
as cardiac channelopathies, coronary heart disease and 
cardiomyopathy in young athletes. Of the 230 athletes 
who were screened between December 2011 and February 
2012, a total of 54 (23%) were referred for additional 
testing because of the presence of abnormalities at the 
stage 1 of the screening. This rate is comparable to that 
reported by Baggish et(17), in which 20% of competitive 
athletes were eligible for additional testing, and higher 
than in other studies(4) (18). 48 athletes (20%) underwent 
additional investigations because of abnormal 
electrocardiographic screening, 6 athletes (2.6%) because 
of abnormal history and examination. The false positive 
rate of electrocardiography was 18.3% and, specifically, 
for stage one screening (history, examination, and ECG), 
it was 20.4%. This rate is comparable with the rate of 
16.9% identified by Baggish et al (17). The spectrum of 
cardiovascular conditions we have found was comparable 
with that by Corrado et al(4, 6, 19) and Wilson et al(20). 
In the present study, 1 athlete had arrhythmogenic right 
ventricular cardiomyopathy, 2 Wolff-Parkinson-White 
syndrome, 1 a long QT syndrome, and 1 atrial fibrillation.  
In the study by Corrado et al(4, 6, 19), the arrhythmogenic 
right ventricular cardiomyopathy and conduction disorders 
were the leading causes of sudden cardiac deaths, whereas 
Maron et al(21) found that, in USA, most sudden cardiac 
deaths arose from hypertrophic cardiomyopathy. 
Interestingly, Wilson et al(22) reported that the prevalence 
of electrocardiographic abnormalities in West Asian and 
Caucasian athletes was comparable (7.9% vs. 5.8%, 
p>0.05). Concerning the practicalities of 
electrocardiography as a screening tool in athletes, 
Bessem et al(23) showed that only 6.3% of patients who 
had undergone electrocardiography required further 
assessment, and the false-positive rate after this screening 
was 11%. This higher false-positive rate may be partly 
related to the population screened, as 7% of athletes had 
been referred for screening because of cardiovascular 
symptoms. Interestingly, Hevia et al(18) showed that the 
rate of abnormal electrocardiography is 6.14%, and only 
3.27% of subjects needed additional tests. Well-trained 
sports physician and cardiologist were involved in this 
study. This improves the quality of the assessment and, 
reasonably, minimised the false positive rate of 
electrocardiography.  Wilson et al(20), in junior athletes 
and physically active schoolchildren, reported that further 
investigations were recommended in 4% (17). This 
relatively low percentage is supposed to be related to the 
high expertise level of cardiologists involved in the study. 
In schoolchildren, the false-positive rate was higher for 
medical questionnaires than for electrocardiography, and 
the prevalence of junior athletes diagnosed with a cardiac 
disease was over twice (0.5%) that of schoolchildren 
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(0.2%). Therefore, selected groups should be screened to 
minimise expenditure, and improve testing accuracy. 
None of the diagnosed athletes were symptomatic, 
confirming that history and examination alone are 
inadequate. Comparing a screening protocol with or 
without electrocardiography, it has been shown that 
electrocardiography improves sensitivity for detection of 
cardiac disorders from 45.5% to 90.9%, and the negative 
predictive value of screening changes from 98.7% to 
99.8%, with a false positive rate of 16.9% (17). Marek et 
al(24) examined the feasibility of a large-scale high school 
electrocardiography screening program (Young Hearts for 
Life [YH4L]). Of 32.561 high school students examined 
between 2006 and 2009, only 2.5% had abnormal 
electrocardiography and required further evaluation. 
Therefore, there is need to implement screening and 
prevent sudden cardiac death in USA. History and 
physical examination alone are inadequate; 
electrocardiography has an independent added value for 
diagnosing cardiac disease, which can lead to sudden 
cardiac death. Most of the studies do not provide 
definitive conclusions about the effect of the different 
screening strategies on the incidence of sudden death in 
athletes. Given the observational design of the study, we 
cannot draw definitive conclusions about the role of 
cardiac screening to reduce the risk of mortality, and 
incidence of cardiac accidents in athletes. However, 
previous studies have proved the effectiveness of 
cardiovascular screening on the incidence of sudden 
cardiac death in athletes(4, 25, 26). Finally our sample 
represented a selected population mainly represented by 
male Arabs (West Asian), and therefore the results should 
not be extrapolated to females or other ethnic groups.. 
 
 
V.  CONCLUSION 
 
 Screening with electrocardiography represents a 
valid clinical strategy to prevent or reduce the risk of 
sudden cardiac death in young athletes. Implementing the 
Lausanne recommendations in the United Arab Emirates,  
screening results will favor the use of electrocardiography. 
On the other hand, the associated increase in overall false-
positive results (20.4%) suggests that some improvements 
are needed, and future large, multicentre prospective trials  
could demonstrate how different screening options affect 
















Total (n = 230) 
 Finding, n (%) 
Appearance  
                    Pale 16(7) 
Heart 
                    Systolic ejection murmur 7(3) 
Abdomen 
                    Palpable spleen 1(0.4) 
                    Inguinal herniotomy scar 1(0.4) 
Genitalia 
                    Hydrocele 2(0.9) 
Skin 
                    Acne 8(3.5) 
                   Chronic urticarial 1(0.4) 
                   Eczema 3(1.3) 
                   Vitiligo 1(0.4) 
                   Chicken pox scar 1(0.4) 
Back 
                   Scoliosis 10(4.3) 
                    Kyphosis 1(0.4) 
Shoulder/Arm 
                    Chronic shoulder instability 4(1.7) 
Elbow/Forearm 
                    Reduced elbow extension 2(0.9) 
                    Cubitus valgus 1(0.4) 
Wrist/Hand 
                     Hand fracture 1(0.4) 
Knee 
                     Genu varus 5(2.2) 
                     Genu valgus 7(3.0) 
                     Anterior cruciate ligament 
reconstruction 
3(1.3) 
                     Meniscectomy 3(1.3) 
Leg/Ankle 
                     Chronic ankle instability 10(4.3) 
                     Tibial varum 6(2.6) 
Foot 
                     Pes planus 60(26.1) 
                     Pes cavus 3(1.3) 
                     Pronated foot 7(3.0) 
                     Supinated foot 1(0.4) 
                     Halux valgus 2(0.9) 
                     Metatarsal abduction 1(0.4) 
                     Metatarsal adduction 1(0.4) 
                     Heel valgus 1(0.4) 
Tab. 3. Distribution of athletes with positive 
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GROUP 1 (training-related) ECG findings 
 





































ER in anterior leads (in isolation or 
combination) 
72 31.3% 




GROUP 2 (training-unrelated) ECG findings 
 
























































TWI in anterior leads 7 3.0% 
TWI in inferior leads 18 7.8% 
TWI in lateral leads 7 3.0% 
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